Imaging-based Thrombolysis Trial in Acute Ischemic Stroke

| Submission date | Recruitment status | Prospectively registered |
|-------------------|----------------------|---|
| 18/11/2005 | No longer recruiting | Protocol |
| Registration date | Overall study status | Statistical analysis plan |
| 05/12/2005 | Completed | Results |
| Last Edited | Condition category | Individual participant data |
| 15/09/2009 | Circulatory System | Record updated in last year |

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Yongjun Wang

Contact details

No.6 Tiantanxili Chongwen District Beijing China 100050 +86 (0)10 67038316 yongjunwang111@yahoo.com.cn

Additional identifiers

Protocol serial number 2004BA714B6

Study information

Scientific Title

Acronym

ITAIS

Study objectives

Thrombolysis with recombinant tissue plasminogen activator (rt-PA) is an effective therapy for ischemic stroke within 3 hours, but most acute ischemic stroke patients arrive at hospital after the 3-hour time window. To select patients by modern magnetic resonance imaging (MRI) technology may extend this time window. Mismatch between perfusion weighted image (PWI) deficits and diffusion weighted image (DWI) lesions putatively represents the penumbra. Intraarterial thrombolysis is also a promising therapy for those patients beyond the 3-hour time window. And until now, there is still no strict randomized controlled trial to compare safety and efficacy between intravenous and intra-arterial thrombolysis with rt-PA.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The protocol has been approved by the Institutional Review Board of the Beijing Tiantan Hospital and other hospitals.

Study design

Prospective multicentre randomised open (assessor-blind) trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Acute ischemic stroke

Interventions

This is a prospective, multicenter, randomized, open, assessor-blind study to assess the efficacy and safety of intra-arterial and intravenous thrombolysis in acute ischemic stroke patients within 3-9 hours time window to use MRI both for patient selection and as a primary efficacy endpoint.

Patients in 3-6 hours time window receive intra-arterial or intravenous thrombolysis with rt-PA randomly. Patients in 6-9 hours time window receive intravenous thrombolysis or conventional therapy randomly. All enrolled patients have standardized DWI, PWI and MRA.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

- 1. Imaging outcome:
- a. Reperfusion was assessed 24 to 48 hours posttreatment and defined as either >=30% reduction of mean transit time (MTT) volume of abnormality or >=2 points improvement on the

TICI grading scheme using MRA

b. The change in infarct lesion volume on DWI from baseline to 24 to 48 hours and 21 days

- 2. Clinical outcome:
- a. Global outcome at day 90:

The combined analysis of the NIHSS, modified Rankin scale (mRS), and Barthel Index (BI) defined as \geq 8 points improvement or scoring 0 to 1 on the NIHSS, a score of 0 to 2 on mRS, and a BI score of 75 to 100.

Modified Rankin Scale 0-1, Barthel Index ≥95, NIHSS 0-1 (inclusive distal motor function)

b. Disability status at day 90:

mRS 0-2 (independent outcome), Barthel Index >=85

Key secondary outcome(s))

1. Functional status at day 30:

mRS (total score), median Barthel Index (total score), median NIHSS (total score), mean/median change from baseline NIHSS (8 points improvement or 0-1)

2. Functional status at day 7:

NIHSS (total score), mean/median change from baseline NIHSS (4 points improvement or 0-1)

3. Functional status at 24 to 48 hours:

NIHSS (total score), mean/median change from baseline

4. Functional status at day 0 (1 and 2 hours after treatment):

NIHSS (total score), mean/median change from baseline

5. Stratified endpoint of NIHSS and mRS:

NIHSS <8: mRS 0 response,

8<=NIHSS<=14: mRS 0-1 response, NIHSS >14: mRS 0-2 response

6. Length of stay in hospital

Completion date

01/06/2007

Eligibility

Key inclusion criteria

- 1. Age 18-75 years
- 2. Clinical signs consistent with the diagnosis of ischemic stroke
- 3. Treatment onset within 3-9 hours after stroke onset
- 4. No prior neurologic event that would obscure the interpretation of the signal and current presenting neurologic deficits (modified Rankin scale $[mRS] \le 1$)
- 5. National Institutes of Health-Stroke-Scale (NIHSS) score >4 and at least moderate limb weakness
- 6. MRI screening to be started within 7.5 hours after stroke onset
- 7. Perfusion abnormality of >2 cm in diameter involving hemispheric gray matter
- 8. Perfusion/diffusion mismatch of ≥20
- 9. Magnetic resonance angiography (MRA) shows that TICI grade is 0 or 1

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

75 years

Sex

All

Key exclusion criteria

- 1. Patients not eligible to receive trial treatment within 30-60 min after completion of MRI1
- 2. Coma
- 3. Stroke symptoms are rapidly improving by the time of randomization
- 4. Major stroke symptoms (>25 to 30 on the NIHSS)
- 5. History of stroke within the previous 6 weeks
- 6. Seizure at the onset of stroke
- 7. Stroke due to a neurointerventional procedure for treatment of a cerebral aneurysm and/or cerebral arteriovenous malformation (stroke due to diagnostic cerebral angiography or cardiac catheterization might be treated)
- 8. Clinical presentation suggestive of subarachnoid hemorrhage, even when the MRI is normal 9. History of intracerebral hemorrhage (ICH) at any time, neoplasm, subarachnoid hemorrhage (SAH), arteriovenous malformation (AVM) or aneurysm
- 10. Presumed septic embolus
- 11. Presumed pericarditis related to recent acute myocardial infarction
- 12. Recent (within 10 to 30 days) surgery, biopsy of a parenchymal organ, or lumbar puncture
- 13. Recent (within 10 to 30 days) trauma (including head trauma), with internal injuries or ulcerative wounds
- 14. Known active inflammatory bowel disease, ulcerative colitis, or diverticular disease
- 15. Any active or recent (within 10 to 30 days) hemorrhage
- 16. Known hereditary or acquired hemorrhagic diathesis. Baseline laboratory values that reveal platelets are <100 000/µl, hematocrit or platelet cell volume <25 volume %, or oral anticoagulant therapy with an international normalized ratio >1.7.
- 17. Pregnancy, lactation, or parturition within the previous 30 days
- 18. Known serious sensitivity to radiographic contrast agents
- 19. Other serious, advanced, or terminal illness such that life expectancy is <1 year
- 20. Any other condition that the physician believes would pose a significant hazard to the patient if fibrinolytic therapy were initiated (e.g. amyloid angiopathy)
- 21. Uncompensated hypertension at study entry or hypertension requiring aggressive treatment to reduce blood pressure to nonhypertensive limits. Uncompensated hypertension is defined as systolic blood pressure >180 mmHg or diastolic blood pressure ≥105 mmHg on 3 repeated measures at least 10 minutes apart. Aggressive treatment is defined as the need for a continuous, parenteral antihypertensive, such as a nitroprusside drip, or the need to administer >3 doses of a parenteral antihypertensive, such as labetalol or Urapidil.
- 22. Evidence of ICH or SAH
- 23. DWI abnormality involving >1/3 of middle cerebral artery (MCA) territory
- 24. No perfusion deficit

25. Any intracranial pathology interfering with the assessment of diffusion and perfusion abnormalities

26. Contraindications to MRI

Date of first enrolment

01/06/2005

Date of final enrolment

01/06/2007

Locations

Countries of recruitment

China

Study participating centre

No.6

Beijing

China

100050

Sponsor information

Organisation

Ministry of Science and Technology of the People's Republic of China (China)

ROR

https://ror.org/027s68j25

Funder(s)

Funder type

Government

Funder Name

th Five-year National Key Technologies R&D Program (ref: 2004BA714B6)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration